Group 1 - Veradermics has officially submitted its initial public offering (IPO) application to fund the commercialization of its oral hair growth medication [1] - The company is developing a non-hormonal therapy for androgenetic alopecia, affecting approximately 80 million people in the U.S. [1] - The company is led by co-founders Dr. Reid Waldman and Tim Dulski [1] Group 2 - Veradermics is preparing to submit late-stage trial data to the FDA for market approval and is conducting patient identification and physician education [1] - The IPO is expected to launch as early as this month, following a $150 million Series C funding round completed in October last year [1] - The offering will be underwritten by Jefferies Financial Group, Leerink Partners, Citigroup, and Cantor Fitzgerald, with plans to list on the New York Stock Exchange under the ticker "MANE" [2]